RxDoctor Payments Data

William Finley

Nurse Practitioner · Albuquerque, NMNPI 1891123485

Payments from drug & device makers

What this record shows

12 manufacturers reported payments, led by Edwards Lifesciences at 54.4% of the total. 2025 is the largest year on record at $2,103, more than ten times the $127 reported in 2021. Among nurse practitioner clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,544in general payments, 2019–2025

Across 54 payments — averaging $65.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$2K
  • Abiomed$919
  • Amgen$153
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$152
  • Ancora Heart, Inc.$113
  • E.r. Squibb & Sons, L.L.C.$78
  • plus $201 from 6 others

What the payments were for

  • Travel & lodging$1,78550%
  • Food & beverage$1,75950%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,544 in reported general payments places this provider in the 95th percentile of 624 nurse practitioner providers in New Mexico.

See all nurse practitioner providers in New Mexico

Medicare billing

Part B allowed, 2024
$38,859
Medicare patients
342
Services billed
646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$30,685
BrilintaTicagrelor38$28,260
Atorvastatin Calcium254$3,719
ClopidogrelClopidogrel Bisulfate152$2,324
Nitroglycerin119$1,845
Metoprolol Succinate123$1,436
Lisinopril132$1,050
Carvedilol102$936
Isosorbide Mononitrate ErIsosorbide Mononitrate52$650
Metoprolol Tartrate76$477
Losartan Potassium58$476
Rosuvastatin Calcium29$455
Amlodipine Besylate48$432
Furosemide51$281
Ezetimibe17$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$57$30,68533 claims
AstraZenecaBrilinta$16$28,26038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 nurse practitioner providers in New Mexico.

Other nurse practitioner in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →